TY - JOUR
T1 - Photodynamic inactivation of candida albicans in blood plasma and whole blood
AU - Sousa, Vera
AU - Gomes, Ana T.P.C.
AU - Freitas, Américo
AU - Faustino, Maria A.F.
AU - Neves, Maria G.P.M.S.
AU - Almeida, Adelaide
N1 - Funding Information:
Thanks are due to the University of Aveiro and FCT/MEC for the financial support to QOPNA (FCT UID/QUI/00062/2019), CESAM (UID/AMB/50017/2019) research units and to the project PREVINE (FCT-PTDC/ASPPES/29576/2017), to FCT/MEC through national funds and the co-funding by the FEDER-Operational Thematic Program for Competitiveness and Internationalization-COMPETE 2020, within the PT2020 Partnership Agreement. Thanks are also due to the Portuguese NMR and Mass Networks.
Funding Information:
Funding: Thanks are due to the University of Aveiro and FCT/MEC for the financial support to QOPNA (FCT UID/QUI/00062/2019), CESAM (UID/AMB/50017/2019) research units and to the project PREVINE (FCT-PTDC/ASPPES/29576/2017), to FCT/MEC through national funds and the co-funding by the FEDER-Operational Thematic Program for Competitiveness and Internationalization-COMPETE 2020, within the PT2020 Partnership Agreement. Thanks are also due to the Portuguese NMR and Mass Networks.
Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2019/12
Y1 - 2019/12
N2 - The few approved disinfection techniques for blood derivatives promote damage in the blood components, representing risks for the transfusion receptor. Antimicrobial photodynamic therapy (aPDT) seems to be a promising approach for the photoinactivation of pathogens in blood, but only three photosensitizers (PSs) have been approved, methylene blue (MB) for plasma and riboflavin and amotosalen for plasma and platelets. In this study, the efficiency of the porphyrinic photosensitizer Tri-Py(+)-Me and of the porphyrinic formulation FORM was studied in the photoinactivation of Candida albicans in plasma and in whole blood and the results were compared to the ones obtained with the already approved PS MB. The results show that FORM and Tri-Py(+)-Me are promising PSs to inactivate C. albicans in plasma. Although in whole blood the inactivation rates obtained were higher than the ones obtained with MB, further improvements are required. None of these PSs had promoted hemolysis at the isotonic conditions when hemolysis was evaluated in whole blood and after the addition of treated plasma with these PSs to concentrates of red blood cells.
AB - The few approved disinfection techniques for blood derivatives promote damage in the blood components, representing risks for the transfusion receptor. Antimicrobial photodynamic therapy (aPDT) seems to be a promising approach for the photoinactivation of pathogens in blood, but only three photosensitizers (PSs) have been approved, methylene blue (MB) for plasma and riboflavin and amotosalen for plasma and platelets. In this study, the efficiency of the porphyrinic photosensitizer Tri-Py(+)-Me and of the porphyrinic formulation FORM was studied in the photoinactivation of Candida albicans in plasma and in whole blood and the results were compared to the ones obtained with the already approved PS MB. The results show that FORM and Tri-Py(+)-Me are promising PSs to inactivate C. albicans in plasma. Although in whole blood the inactivation rates obtained were higher than the ones obtained with MB, further improvements are required. None of these PSs had promoted hemolysis at the isotonic conditions when hemolysis was evaluated in whole blood and after the addition of treated plasma with these PSs to concentrates of red blood cells.
KW - Antimicrobial Photodynamic Therapy
KW - Blood plasma
KW - Candida albicans
KW - Methylene blue
KW - Porphyrins
UR - http://www.scopus.com/inward/record.url?scp=85075072289&partnerID=8YFLogxK
U2 - 10.3390/antibiotics8040221
DO - 10.3390/antibiotics8040221
M3 - Article
C2 - 31766190
AN - SCOPUS:85075072289
SN - 2079-6382
VL - 8
JO - Antibiotics
JF - Antibiotics
IS - 4
M1 - 221
ER -